Monoclonal Gammopathy

Research

The term monoclonal gammopathy of undetermined significance was coined at Mayo Clinic to describe this condition. Extensive research is ongoing at Mayo to understand all facets of this condition, its diagnosis, prevention and treatment.

The risk factors for this condition and for its progression to more serious cancer (such as myeloma) are being studied at Mayo by clinicians and epidemiologists. Laboratory scientists are studying the roles that genetic factors, cytokines (growth factors for cells) and new blood vessel formation (angiogenesis) play in this condition and its progression.

Clinical researchers at Mayo are conducting studies using novel drugs to help slow down the disease and to identify patients at highest risk who may benefit from therapy or closer observation.

Research Publications

See a list of publications by Mayo Clinic researchers and physicians on PubMed, a service of the National Library of Medicine and the National Institutes of Health.